Weekly Recap: Wegovy patent non-infringement suit and $25 Oppenheimer PT
Viatris, Inc. (NASDAQ:VTRS) is challenging Novo Nordisk in Delaware, suing for a declaratory judgment that its proposed generic Wegovy doesn’t infringe the single—dose pen method patent, as Oppenheimer pegs VTRS at a $25.00 price target amid the legal fight.Previous Week RecapThis is an AI-generate…